• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Atypicals for Bipolar: And Then There Were Five

Atypicals for Bipolar: And Then There Were Five

February 1, 2005
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
We knew it was about to happen. We just didn’t know it would happen all at once. Between July and September of 2004, Seroquel, Geodon, and Abilify sequentially won approval for the treatment of manic episodes in bipolar disorder. Which means that now all of the newer atypical antipsychotics have been admitted to the bipolar club, which until December 2003 (Risperdal’s approval date), was monopolized by Zyprexa.

To help you cut through the confusion, here’s a comparison chart updating you on what each drug is or isn’t approved for:
Table: Atypical antipsychotics approved for bipolar disorder (as of Feb 2005)
Table: Atypical antipsychotics approved for bipolar disorder (as of Feb 2005)

Some comments on the chart:

  1. You’ll notice that all five are approved for the acute treatment of a manic (and also mixed) episode. These approvals are all for monotherapy at the doses listed in the chart, and effectiveness was established with double-blind, placebo-controlled trials of three weeks duration. As an aside, conventional antipsychotics have had well-established efficacy as monotherapy for manic episodes for years, although only Thorazine applied for and received FDA approval for this.

  2. Three of the atypicals, Zyprexa, Risperdal, and Seroquel, are approved for "combination treatment with Lithium or Depakote.” What does this mean, exactly? Patients with bipolar disorder who were in the midst of a manic or mixed episode were recruited for these trials. They had all been on lithium or Depakote for at least two weeks, and yet they were still manic. They were then randomly divided into two groups: one group was given adjunctive antipsychotic, and the other group was given placebo. The primary outcome was improvement in the Young Mania Rating Scale (YMRS). The trials were typically three weeks in length, and at endpoint the groups on adjunctive antipsychotics had a lower average score on the YMRS than the groups taking adjunctive placebo. Thus, these studies prove the not-exactlyastonishing fact that manic patients improve more quickly when you add an antipsychotic to their mood stabilizer.

  3. Zyprexa has approval for one thing that none of the other atypicals can claim: “maintenance monotherapy.” This labeling was based on one unpublished study in which 361 bipolar patients who had responded to Zyprexa during an initial two week open-label treatment phase were then randomized to either continued Zyprexa or placebo. After one year, only about 20% of Zyprexa-treated patients had relapsed vs. about 60% of those on placebo. You should note, however, that we obtained this information from the Zyprexa website* and the presentation there was a very brief summary without the details needed to evaluate methodology. Nonetheless, their study methods passed FDA muster, which is usually a good sign. Whether similar maintenance data exists for the other atypicals is unknown at this point. No double-blind trials have been published, but long-term open label data exists for some atypicals (see Current Psychiatry April 2004 for a brief review).

  4. The chart doesn’t include Symbyax, which is a combination of Zyprexa and Prozac and is the only medication approved for the treatment of depressive episodes in bipolar disorder. We’ll review this in a future issue on bipolar disorder.

  5. A word on dosing. You’ll notice that the starting doses of the newer atypicals are rather high, certainly higher than doses recommended for patients with schizophrenia. This likely reflects the ardent desires of manufacturers to prove their drugs work, although less cynically, one can argue that there is indeed more urgency in treating an acute manic episode than in treating a chronic condition such as schizophrenia. But clinically, these high starting doses have led psychiatrists to cause a variety of side effects in their patients. For example, many a patient will keel over into longterm slumber-land when confronted with Geodon 40 mg BID (which is Pfizer’s recommended starting dose), while other patients will dance the akathisia jig when started on Abilify 30 mg QD (BMS’s recommendation). In fact, the Abilify package insert seems to backtrack on the 30 mg starting dose, declaring that 15% of patients had to be decreased to 15 mg QD because of tolerability issues. The bottom line is that PDR recommended dosages for bipolar disorder are often unrealistically high. On the other hand, clinicians have learned to take Seroquel’s package insert seriously, finding that you really have to push Seroquel to the 400 to 800 mg range to get a good response. Just advise your patients to invest in a good Sealy Posturepedic for the first week or so, because that’s where they’ll be spending most of their time.

General Psychiatry
KEYWORDS bipolar_disorder
Carlat 150x150
Daniel Carlat, MD

20 Years of The Carlat Report

More from this author
www.thecarlatreport.com
Issue Date: February 1, 2005
SUBSCRIBE NOW
Table Of Contents
The Story of Clozapine
Atypicals for Bipolar: And Then There Were Five
Philip G. Janicak, M.D. On Using Atypical Antipsychotics
Clozapine: Is it truly better than the rest?
Metabolic Side Effects: Here We Go Again!
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto11543850.jpg
    General Psychiatry

    Elvis, Adderall, and a Broken Heart - Part 1

    A new medical investigation changes our understanding of Elvis Presley’s untimely death and offer some pearls for modern psychiatric practice.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.